Jiangsu QYuns Therapeutics Initiates Phase III Trial for Skin Disease Candidate QX005N
Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509), a biopharmaceutical company based in China, has announced...
HuidaGene and Synthego Form Strategic Partnership for CRISPR-Based Therapies
HuidaGene (Shanghai) Biotechnology Co., Ltd, a clinical-stage biotechnology company based in China, has entered into...
Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury
Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced...
Zelgen Biopharmaceuticals Gets NMPA Approval for Jacktinib Vitiligo Trial in Adolescents and Adults
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received...
Hengrui Pharmaceuticals’ Vitiligo Treatment SHR0302 and Diabetes Drug HRS9531 Get Green Light from China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading biopharmaceutical company based in China, has...
Fosun Pharma Rumored to Fully Acquire Subsidiary Henlius Pharmaceutical, Shares Suspended
Rumors are circulating, as reported by Bloomberg citing insiders, that Shanghai Fosun Pharmaceutical (Group) Co.,...
Amgen’s Bkemv Becomes First Biosimilar to Challenge AstraZeneca’s Soliris with FDA Approval
Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company, has been granted regulatory approval by the...
Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
Jiangxi Rimag Group Sets IPO Price Range for Hong Kong Debut, Aims to Raise Up to USD 2.15 per Share
Jiangxi Rimag Group Co., Ltd, a leading medical imaging services provider based in China, has...
IVD Medical Holding Ltd Enters Non-Binding MoU with Chinese Chemiluminescence IVD Company for Potential Collaboration
IVD Medical Holding Ltd (HKG: 1931), a leading in vitro diagnostic (IVD) company based in...
BMS Strikes Deal with Prothena for Potential Disease-Modifying Neurology Drug PRX019
Bristol Myers Squibb (BMS; NYSE: BMY) has executed an exclusive global licensing agreement with Prothena...
Sino Medical Sciences’ Innovative Drug-Coated Stent System Accepted for NMPA Review
Sino Medical Sciences Technology Inc. (SHA: 688108), a China-based medical technology company, has announced that...
Gilead Partners with Cartography Biosciences to Develop Therapies for Triple-Negative Breast Cancer
Gilead Sciences (NASDAQ: GILD) has entered into a collaboration agreement with Cartography Biosciences, a US-based...
Sanofi Partners with Bluecrux to Enhance Supply Chain with AI Technologies
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, is enhancing its supply chain strategy with...
Bio-Thera Solutions Partners with STADA for European Commercialization of Golimumab Biosimilar
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced a licensing...
Roche Extends Long-Standing Partnership with Hitachi High-Tech to Innovate Diagnostic Solutions
Roche (SWX: RO), a major Swiss pharmaceutical company, has renewed its 46-year partnership with Japan’s...
Asahi Kasei Moves to Fully Acquire Swedish Rare Disease Biopharma Calliditas in All-Cash Deal
Japan’s Asahi Kasei Corporation (TYO: 3407) has announced an all-cash offer to fully acquire the...
Alphamab Oncology’s KN046 Misses Primary Endpoint in Phase III Pancreatic Cancer Study
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has announced disappointing results from...
3SBio Secures License for Semaglutide Biosimilar from Hybio Pharmaceutical
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced a licensing agreement...
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA),...